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Introduction
Autoreactive T cells are primarily eliminated in the thymus
by negative selection (central tolerance). Some of the
autoreactive T cells, however, may escape from negative
selection and are released into the periphery. These self-
reactive T cells are exquisitely regulated, and their activa-
tion can result in autoimmune diseases. There is
accumulating evidence that, in addition to activation-
induced cell death or anergy, T-cell-mediated dominant
control of self-reactive T cells represents one mechanism
for maintaining immunological tolerance [1–3]. Studies
conducted in a number of experimental models have
demonstrated the existence of regulatory T-cell subsets
that prevent activation of autoreactive T cells. Recently, a
subset of CD4+ T cells was identified that is present on
5–10% of CD4+ T cells in normal naïve mice and
expresses CD25 (the α-chain of IL-2 receptor) [4,5].
Functional analysis of murine CD4+CD25+ T cells showed
that those cells, which constitutively express cytotoxic
T-lymphocyte antigen (CTLA)-4 [6–8], fail to proliferate or
secret cytokines in response to polyclonal or antigen-spe-
cific stimulation, but inhibit the activation of conventional
responsive T cells [1–3,8,9]. The suppressive activity of
the CD4+CD25+ T cells depends on signaling via the neg-
ative regulator of T-cell activation CTLA-4 [7] and requires
a cell–cell interaction that possibly involves cell surface
bound transforming growth factor (TGF)-β1 [1,10]. It has
been shown that B7/CD28 costimulation is essential for
the development and homeostasis of the CD4+CD25+
regulatory T cells [6], which play critical roles not only in
AICD = activation-induced cell death; CTLA = cytotoxic T-lymphocyte antigen; ELISA = enzyme-linked immunosorbent assay; FITC = fluorescein
isothiocyanate; IL = interleukin; PE = R-phycoerythrin; PG = proteoglycan; PGIA, proteoglycan-induced arthritis; SCID = severe combined immun-
odeficient; TCR = T-cell receptor; TGF = transforming growth factor; WT = wild-type.
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Abstract
Accumulating evidence suggests that regulatory T cells play a
crucial role in preventing autoimmunity. Recently, a naturally
occurring CD4+CD25+ T-cell subset that is anergic and also
suppressive has been shown to suppress autoimmunity in
several animal models. We used proteoglycan-induced arthritis
(PGIA) as a study model to investigate the role of the
CD4+CD25+ regulatory T cells in autoimmune arthritis. There
was no significant change in the percentage of CD4+CD25+
T cells during the immunization period when proteoglycan- or
ovalbumin-immunized BALB/c and C57BL/6 mice were
compared. An adoptive transfer study showed that the
CD4+CD25+ T cells did not protect severe combined
immunodeficient mice from arthritis when they were
cotransferred with splenocytes from arthritic animals. Similarly,
depletion of the CD4+CD25+ T cells did not enhance the onset
of the disease or disease severity in severe combined
immunodeficient mice. Moreover, CD28-deficient mice, which
have very few CD4+CD25+ T cells, were highly resistant to
PGIA. These findings indicate that the CD4+CD25+ regulatory
T cells may not play a critical role in controlling PGIA.
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preventing autoimmunity but also in controlling tumor
immunity and transplantation tolerance [2,11].
Proteoglycan-induced arthritis (PGIA) is a novel autoim-
mune murine model that is induced by systemic immuniza-
tion of BALB/c mice with cartilage proteoglycans [12,13].
The development of PGIA is based on the cross-reactive
immune response between immunizing human and mouse
(self) cartilage proteoglycans in genetically susceptible
BALB/c mice [12,13]. Several lines of evidence indicate
T-cell involvement in the pathogenesis of PGIA. First,
CD4+ T cells selectively proliferate in response to proteo-
glycan antigens [14]. Second, prevention of arthritis can
be achieved by in vivo treatment with anti-CD4 mono-
clonal antibodies [15]. Third, arthritis can be transferred to
naïve BALB/c or severe combined immunodeficient
(SCID) mice using T and B cells from arthritic animals
[16–18]. Fourth,. a proteoglycan-specific T-cell hybridoma
(T-helper-1 type) can induce arthritis in BALB/c mice [19].
Finally, CD4+ T cells from arthritic animals are resistant to
activation-induced cell death [20]. These data suggest a
breakdown of peripheral tolerance and accumulation of
autoreactive T cells in the periphery.
In order to determine whether CD4+CD25+ regulatory
T cells play a role in the development of PGIA, we moni-
tored the CD4+CD25+-expressing regulatory T cells in
mice with PGIA during an entire immunization period. We
also transferred purified CD4+CD25+ T cells from naïve
BALB/c mice together with spleen cells from arthritic
animals, or alternatively transferred CD4+CD25+-
depleted spleen cells from arthritic animals into SCID
mice, and then monitored disease development in SCID
mice. In addition, we examined disease incidence in
CD28-deficient mice, which have deficiency in
CD4+CD25+ T cells. Our data suggest that the
CD4+CD25+ regulatory T cells might not be essential for
controlling the development of PGIA.
Materials and methods
Antigen, mice and immunization
High-density cartilage proteoglycan (aggrecan) was puri-
fied from human cartilage, by CsCl gradient centrifuga-
tion, and depleted of glycosaminoglycan side chains as
described previously [21]. Female BALB/c mice
(National Cancer Institute, Friedrich, MD, USA, or The
Jackson Laboratory, Bar Harbor, ME, USA) and CD28-
deficient mice (The Jackson Laboratory) were immunized
intraperitoneally with cartilage proteoglycan (100µg
protein) in complete Freund’s adjuvant on day 0, and
boosted with proteoglycan in incomplete Freund’s adju-
vant on days 21 and 42. Female SCID mice on a BALB/c
background (NCI/NCrC.B-17-scid/scid), aged 8–12
weeks or young retired breeders, were purchased from
the National Cancer Institute and maintained under
germ-free conditions.
Assessment of arthritis
A standard scoring system, based on swelling and
redness of each paw, was used for the assessment of the
severity of disease. The first clinical symptom of swelling
was recorded as the time of onset of arthritis. Joint
swelling was scored (ranging from 0 to 4 in each paw)
and expressed as acute cumulative arthritis score, result-
ing in a possible maximum severity score of 16. Typically,
in the primary form of PGIA, BALB/c mice developed
swelling and redness in one or more limbs 7–14 days
after the third injection with proteoglycan and adjuvant. In
the transfer system, recipient SCID mice developed a
more uniform disease from day 10 after transfer, with
involvement of nearly all peripheral joints.
Flow cytometry analysis
The CD4+CD25+-expressing T cells were identified by
staining spleen cells with fluorescein isothiocyanate (FITC)-
labeled anti-CD4 and biotin-labeled anti-CD25 followed by
CyChrome-labeled streptavidin (BD PharMingen, San
Diego, CA, USA), and analyzed on a flow cytometer
(Beckton Dickinson, San Jose, CA, USA). For analysis of
intracellular CTLA-4, spleen cells were first stained with the
above fluorescence-labeled antibodies, fixed and rendered
permeable, and stained with R-phycoerythrin (PE)-labeled
anti-CTLA-4 using a Cytofix/Cytoperm kit (BD PharMingen).
Purification of CD4+CD25+ and CD4+CD25– T cells and
cell transfer in SCID mice
The CD4+CD25+ T cells were purified using a protocol
described previously [6]. Briefly, CD4+ T cells were iso-
lated from spleens of 10- to 12-week-old, naïve, BALB/c
mice by negative selection using CD4-enrichment
columns (R&D System, Minneapolis, MN, USA). Purified
CD4+ T cells were incubated with PE-labeled anti-CD25,
and the stained cells were incubated with anti-PE
microbeads (Miltenyi Biotech Inc., Auburn, CA, USA). The
CD25+ cells were selected on an LS+ column (Miltenyi
Biotech Inc.). The purity of the CD4+CD25+ T cells was
approximately 90%. The CD4+CD25– T cells, which did
not bind to magnetic beads, were collected from the flow
through the washing steps (purity >98%). A total of
5×10 5 CD4+CD25+ or CD4+CD25– T cells were
injected intraperitoneally, along with 1×107 spleen cells
from arthritic animals that were depleted of CD25+ cells
and 100µg proteoglycan, into SCID mice.
Depletion of CD4+CD25+ T cells and cell transfer
Spleen cells from arthritic animals were depleted of
CD25+ cells using negative selection as described above
(0.5µg PE-labeled anti-CD25 per 1×106 cells). The
depletion of CD4+CD25+cells was detected by flow
cytometry. Typically, less than 0.3% of the depleted cells
expressed CD25. a total of 1×107 CD25+ and CD25–
spleen cells, together with 100µg proteoglycan, were
injected intraperitoneally into SCID mice.Arthritis Research & Therapy    Vol 5 No 2 Bardos et al.
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In vitro suppression assay
CD4+CD25+ T cells (1×104) isolated from naïve BALB/c
mice were mixed with CD4+CD25- T cells (5×104) from
arthritic mice in the presence of irradiated syngenic
splenocytes as antigen-presenting cells (7.5 × 104) with
1µg/ml soluble anti-CD3 for 3 days or 50µg/ml proteogly-
can for 5 days, and T-cell proliferation was determined by
[3H]thymidine incorporation.
Measurements of antigen-specific T-cell responses,
antibodies, and cytokine production
Antigen-specific T-cell responses were measured in
quadriplicate samples of spleen cells (3×105 cells/well)
cultured in the presence of 50µg proteoglycan protein/ml.
T-cell proliferation was assessed on day 5 by [3H]thymi-
dine incorporation [14,22]. Antigen (proteoglycan)-spe-
cific interferon-γ, IL-10, and IL-4 production by T cells was
determined in media collected on day 4 using capture
enzyme-linked immunosorbent assays (ELISAs) from
BioSource International, Inc. (Camarillo, CA, USA). For
induction of TGF-β1, spleen cells were cultured in serum-
free medium X-Vivo-20 (BioWhittaker, Inc., Walkersville,
MD, USA) in the presence of proteoglycan. Total TGF-β1
was measured after acidification to activate latent TGF-β,
followed by neutralization using an ELISA kit from
Promega (Madison, WI, USA).
Maxisorp immunoplates (Nunc, Rochester, NY, USA) were
coated with human or mouse cartilage proteoglycans
(0.1µg protein/100µl per well) for ELISA, and free
binding capacity of the wells was blocked by 1% fat-free
milk in phosphate-buffered saline [23–25]. Sera were
applied at increasing dilutions and isotypes of proteogly-
can-specific antibodies were determined using peroxi-
dase-conjugated rat antimouse IgG1 or IgG2a secondary
antibodies (Zymed, South San Francisco, CA, USA) as
previously described [24,26]. Serum antibody levels were
calculated according to mouse IgG1 and IgG2a standards.
Mouse IgG1 and IgG2a standards were purified by
sepharose-coupled protein G from irrelevant (non-proteo-
glycan-specific) monoclonal antibody-containing ascites
fluids and coated directly onto the microplate’s surface.
Statistical analysis
Statistical analysis was performed using SPSS v7.5
(SPSS, Chicago, IL, USA). The Mann–Whitney and
Wilcoxon tests were used for intergroup comparisons.
P<0.05 was considered statistically significant.
Results
Lack of correlation between development of arthritis
and expression of CD4+CD25+ regulatory T cells in PGIA
To elucidate the role of these regulatory T cells in autoim-
mune arthritis, we first followed up the CD4+CD25+-
expressing regulatory T cells in mice with PGIA during the
entire course of immunization. To exclude the possibility
that different CD4+CD25+-expressing T cells may be a
strain- and/or antigen-dependent phenomenon, we immu-
nized BALB/c mice (PGIA-susceptible strain) and
C57BL/6 (arthritis-resistant strain) with human cartilage
proteoglycan or ovalbumin. As shown in Fig.1, BALB/c
mice immunized with human cartilage proteoglycan
started to develop arthritis after the third injection and the
incidence of arthritis reached 100% at day 72 following
the third immunization, whereas BALB/c mice immunized
with ovalbumin or C57BL/6 mice immunized with proteo-
glycan were completely resistant to PGIA. The
CD4+CD25+-expressing T cells detected 14 days after
each immunization from each experimental group were
similar during the entire course of immunization (Fig.2a).
This observation suggests that the CD4+CD25+ regula-
tory T cells might not be involved in the development of
PGIA. Although it has been shown that the CD4+CD25+
regulatory T cells can suppress the development of
autoimmunity, a recent report [27] demonstrated that
depletion of the CD4+CD25+ T cells is necessary but not
sufficient for induction of autoimmune gastritis.
It has been shown that the CD4+CD25+ regulatory T cells
express CTLA-4 [6–8], which is a negative regulator of
T-cell activation. The suppressive activity of the
CD4+CD25+ regulatory T cells may in part be ascribed to
signaling through CTLA-4. CTLA-4 may transduce an acti-
vating signal to CD4+CD25+ regulatory T cells [2].
Although we did not detect any significant decrease in
numbers of the CD4+CD25+ regulatory T cells between
proteoglycan-immunized BALB/c and C57BL/6 mice, this
might be due to reduced expression of CTLA-4 in the
CD4+CD25+ regulatory T cells from proteoglycan-immu-
nized BALB/c mice. To test this possibility, we then
detected CTLA-4 expression on the CD4+CD25+ regula-
tory T cells using intracellular staining. There was no sig-
nificant difference between levels of CTLA-4 expression in
the CD4+CD25+  regulatory T cells from each group
(Fig.2b). This finding excludes the possibility that reduced
expression of CTLA-4 in the CD4+CD25+ regulatory
T cells from BALB/c mice with PGIA may mediate the
induction of the disease.
CD4+CD25+ regulatory T cells may not control
autoimmune arthritis
To further investigate whether the CD4+CD25+ T cells
play a role in PGIA, we performed adoptive transfer experi-
ments using SCID mice as recipients. Purified
CD4+CD25+ regulatory T cells (3–20×105) from naïve
BALB/c mice, together with 107 spleen cells from arthritic
mice that were depleted of CD25+ T cells and 100µg pro-
teoglycan, were injected intraperitoneally into SCID mice
[18], and the incidence and severity of disease were moni-
tored. Note that we used different ratios of the
CD4+CD25+ regulatory T cells to the effector cells, and
we did not observe any suppression of arthritis develop-Available online http://arthritis-research.com/content/5/2/R106
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ment. As a control, the same number of CD4+CD25–
T cells, together with arthritogenic spleen cells that were
depleted of CD25+ cells, and proteoglycan, were also
adoptively transferred into SCID mice. The transfers of
CD4+CD25+ T cells did not have any impact on incidence
and severity of the disease in SCID mice as compared
with transfer of CD4+CD25– T cells (Fig.3a), suggesting
that the CD4+CD25+ regulatory T cells did not protect
SCID mice from arthritis. To further verify these results, a
depletion experiment was conducted. Spleen cells from
arthritic animals, either depleted of CD25+ cells or without
depletion, were injected into SCID mice together with pro-
teoglycan. The incidence and severity of arthritis in SCID
mice receiving spleen cells containing CD25+ cells or
spleen cells depleted of CD25+ cells were identical
(Fig.3b). Proteoglycan-specific T-cell proliferation and
production of IL-4, interferon-γ, IL-10, TGF-β1 and antipro-
teoglycan autoantibodies were comparable in both trans-
fer groups (Fig.3c). The inability of the CD4+CD25+
regulatory T cells to suppress PGIA was not due to loss of
their suppression activity, because in vitro the
CD4+CD25+ T cells could effectively inhibit the prolifera-
tion of the CD4+CD25– T cells (Fig.3d, left panel). Inter-
estingly, proteoglycan-induced proliferation of
CD4+CD25- T cells could not be inhibited by the
CD4+CD25+ T cells (Fig.3d, right panel), which is consis-
tent with a recent report that the effective function of the
CD4+CD25+ regulatory T cells is T-cell receptor (TCR)
specific [28]. Collectively, our data suggest that the
CD4+CD25+ regulatory T cells may not be involved in the
development of PGIA.
Figure 1
Incidence and severity of arthritis in BALB/c mice. BALB/c and
C57BL/6 mice (15 mice/group) were immunized with proteoglycan or
ovalbumin in complete Freund’s adjuvant (day 0), and boosted with
proteoglycan or ovalbumin in incomplete Freund’s adjuvant at days 21
and 42. The incidence and severity of arthritis was determined.
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Figure 2
The number of CD4+CD25+-expressing regulatory T cells from
BALB/c and C57BL/6 mice during immunization. (a) BALB/c and
C57BL/6 mice, immunized with proteoglycan (PG) or ovalbumin
(OVA), were killed at 14 days after each immunization, and levels of
expression of the CD4+CD25+ T cells were determined by flow
cytometry. *The CD4+CD25+ T cells from naïve BALB/c and C57BL/6
mice were also determined. (b) Cytotoxic T-lymphocyte antigen
(CTLA)-4 expression on the CD4+CD25+ T cells from PG- or OVA-
immunized animals (after the 3rd injection) was determined.
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Figure 3
The incidence and severity of arthritis in severe combined immunodeficient (SCID) mice. (a) SCID mice (six to eight mice/group) were
intraperitoneally injected with 5×105 purified CD4+CD25+ or CD4+CD25– T cells from naïve BALB/c mice, together with 1×107 CD25-depleted
spleen cells from arthritic animals and 100µg proteoglycan (PG). The incidence and severity of arthritis was determined. One representative
experiment of two is shown. (b) A total of 1×107 spleen cells or spleen cells depleted of CD25-expressing cells from arthritic animals, together
with 100µg PG, were transferred intraperitoneally into SCID mice. Disease incidence and severity were determined. (c) Spleen cells from SCID
mice that received cell transfer of the CD4+CD25+ or CD4+CD25– T cells and CD25-depleted spleen cells from arthritic mice were cultured in
96-well plate for 5 days in the presence of 25µg/ml PG, and PG-specific T-cell proliferation was determined using [3H]thymidine incorporation,
and expressed as stimulation index (SI; a ratio of incorporated [3H]thymidine [counts per minute] in antigen-stimulated cultures relative to counts
per minute in nonstimulated cultures). PG-specific interferon-γ, IL-10 and IL-4 production by T cells was determined in media collected at day 4
using capture enzyme llinked immunosorbent assays (ELISAs). For induction of transforming growth factor (TGF)-β1, spleen cells were cultured in
serum-free medium X-Vivo-20 (BioWhittaker, Inc.) in the presence of PG. Total TGF-β1 was measured after acidification to activate latent TGF-β,
followed by neutralization using an ELISA kit from Promega. Serum antibody levels were determined by ELISA using mouse IgG1 and IgG2a as
standards. (d) Purified splenic CD4+CD25+ T cells from naïve BALB/c mice were cocultured with CD4+CD25– T cells from arthritic mice in the
presence of irradiated splenocytes and anti-CD3 for 72 hours or PG for 5 days at 37°C, and T-cell proliferation was determined by [3H]thymidine
incorporation. **P<0.005.
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1CD28-deficient mice have severely reduced CD4+CD25+
regulatory T cells but are resistant to PGIA
It has been shown that CD28–B7 interaction is essential
for the homeostasis of the CD4+CD25+ regulatory T cells
that control autoimmune diabetes [6]. Consistent with that
report, the expression of CD4+CD25+ regulatory T cells
was found to be significantly reduced as compared with
that in wild-type BALB/c mice (Fig.4a). To investigate
whether a deficiency in the CD4+CD25+ regulatory T cells
may lead to an increase in the development of PGIA, we
immunized wild-type and CD28-deficient BALB/c mice
with proteoglycan, and disease incidence was monitored.
In contrast to the report in autoimmune diabetes [6],
CD28-deficient BALB/c mice were highly resistant to
induction of arthritis, albeit at a low percentage of the
CD4+CD25+ regulatory T cells observed in these mice
(Fig.4b). Note that T cells from proteoglycan-immunized
CD28-deficient mice proliferate in response to proteogly-
can stimulation, albeit at a rate lower than that in wild-type
T cells (Fig.4c), suggesting that CD28-deficient T cells
can be effectively primed.
Discussion
A controlled balance between initiation and downregula-
tion of immune responses (peripheral tolerance) is impor-
tant for maintaining immune homeostasis, whereas
dysfunctional immune regulation may lead to chronic
inflammation or autoimmunity [29]. The CD4+CD25+ reg-
ulatory T cells have been shown to suppress autoimmu-
nity in several animal models [2]. To evaluate the role of
the CD4+CD25+ regulatory T cells in PGIA, three
approaches were used. First, the numbers of the
CD4+CD25+ cells in spleens of susceptible versus resis-
tant or ovalbumin immunized mice were assessed by flow
cytometry at day 14 following immunization. No signifi-
cant change in the numbers of the CD4+CD25+ cells
was observed among experimental groups tested
(Fig.2a). Moreover, the levels of expression of CTLA-4 in
the CD4+CD25+ cells was similar between groups.
These data suggest that the CD4+CD25+ cells may not
be involved in the development of PGIA. Although the
immune system had been perturbed by immunization,
CD4+ T cells isolated 14 days after immunization of each
group did not show significant increase in CD25 expres-
sion as compared with that in naïve mice, suggesting that
T cells activated by immunization had become resting
memory T cells.
To further evaluate the role of the CD4+CD25+ cells in
PGIA, an adoptive transfer system was employed. Differ-
ent ratios of activated effector cells (CD25-depleted
spleen cells) to CD4+CD25+ cells were tested in our
cotransfer experiments. No suppression of development
of PGIA in SCID mice was observed. Although one
could argue that the ratio of effector cells to regulatory
cells is not sufficiently great to inhibit disease, we tested
Available online http://arthritis-research.com/content/5/2/R106
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Figure 4
Resistance to proteoglycan-induced arthritis (PGIA) in CD28-deficient mice. (a) The expression of CD4+CD25+ T cells in naïve wild-type (WT) and
CD28-deficient BALB/c mice was determined. (b) Wild-type and CD28-deficient BALB/c mice were immunized with proteoglycan (PG) in
complete Freund’s adjuvant, and boosted in incomplete Freund’s adjuvant at days 21 and day 42. The mice developed arthritis after the third
immunization. The incidence of arthritis in WT and CD28-deficient BALB/c mice was monitored. (c) CD4+ T cells (1×106/ml) from PG-immunized
WT and CD28-deficient mice were cultured for 5 days with antigen-presenting cells (2500 rad-irradiated syngenic splenocytes, 2×106/ml) in the
presence of proteoglycan (10, 25 and 50µg/ml). The cell proliferation was determined by [3H]thymidine incorporation.
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CD28-/-a wide range of ratios of effector cells to regulatory cells
(5–30:1) in our transfer system, and similar results were
observed. We did not observe any inhibition at the ratios
used in the present study. However, we cannot com-
pletely exclude the possibility that 1–4:1 ratios may be
required for suppression of PGIA. In view of the pub-
lished literature, this is unlikely because most studies of
this type used ratios greater than 20:1 [6]. This finding
is further supported by the evidence that adoptive trans-
fer of CD25-depleted splenocytes from arthritic mice
does not exacerbate disease in SCID mice. The
CD4+CD25+ T cells are functionally normal because the
CD4+CD25+ cells can significantly inhibit the prolifera-
tion of the CD4+CD25- cells induced by TCR stimulation
(Fig.3d, left panel). No alteration in IL-10 and TGF-β pro-
duction could be detected in two transfer groups
(Fig.3c). Taken together, our data suggest that the
CD4+CD25+ regulatory T cells may not regulate the
development of PGIA.
We found that CD28-deficient mice, which have a low fre-
quency of CD4+CD25+ T cells, are resistant to PGIA.
Although one may argue that, in the absence of CD28,
T-cell priming by proteoglycan immunization may be
defective. However, CD28-deficient T cells from proteo-
glycan-immunized animals can proliferate in response to
proteoglycan stimulation in vitro, albeit at a rate lower than
that in wild-type T cells, which is consistent with the report
by Oliveira-dos-Santos et al. [30]. It has been demon-
strated that, in the absence of CD28 engagement, T cells
require very high TCR occupancy and prolonged stimula-
tion, whereas CD28 costimulation allows T cells to
respond to lower degrees of TCR occupancy [30,31]. In
support of this observation, CD28–/– mice can still mount
immune responses, which vary in magnitude and effi-
ciency depending on the antigen or infectious agent
[30,32]. Our results and those reported by others [30]
suggest that CD28 may regulate the threshold for T-cell
activation. In support of this notion, immunization of CD28-
deficient mice with high concentrations of myelin basic
protein induces experimental autoimmune encephalo-
myelitis at similar prevalence and severity as in wild-type
mice [30]. Our data suggest that the CD4+CD25+ regula-
tory T cells might be important for controlling spontaneous
models of autoimmunity but not for induced models of
autoimmunity. In induced models of autoimmunity, the
CD28–B7 interaction has been shown to regulate disease
susceptibility by rendering autoreactive T cells anergic, or
alternatively by upregulating the threshold for autoreactive
T-cell activation [30]. Furthermore, we previously showed
that impaired Fas-mediated activation-induced cell death
(AICD) of autoreactive T-helper-1 cells may be responsi-
ble for the development of PGIA [20]. Therefore, AICD
and/or T-cell anergy, but not the CD4+CD25+ regulatory
T cells, may be responsible for deletion or inactivation of
autoreactive T cells in autoimmune arthritis.
Conclusion
Our results showed that the percentage of the
CD4+CD25+ regulatory T cells does not change during
the development of PGIA. The CD4+CD25+ regulatory
T cells do not protect SCID mice from arthritis when they
are cotransferred with spleen cells from arthritic mice and
proteoglycan into SCID mice. Transfer of spleen cells from
arthritic mice, depleted of the CD4+CD25+ regulatory
T cells, into SCID mice does not accelerate the disease.
Furthermore, CD28-deficient mice, which are deficient for
CD4+CD25+ T cells, are resistant to PGIA. Our data
suggest that the CD4+CD25+ regulatory T cells may not
be essential for controlling experimentally induced autoim-
mune arthritis.
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